MarginsXMarginsX
Home › Markets › Health Care › CYRX

CryoPort Inc. (CYRX)

CYRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$19.80
-0.45% on the day
Market cap
$1.0B
Small cap
Revenue · 2025
$176.2M
+12.4% on 2024
Net income · 2025
$78.3M
44.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1124524/000110465926024180/0001104659-26-024180-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCYRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001124524
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2025

LineValue
Revenue$176.2M
Net income$78.3M
Operating income-$36.8M
Net margin44.4%
Operating margin-20.9%
Revenue growth+12.4%
Cash$250.5M
Total assets$765.0M
P/E (computed)12.8×
P/S (computed)5.7×

Warning signs

Cash runway
Cash-flow positive
$279.2M cash at September 30, 2026
Share count, 1 year
+1.3%
2025-10-31 to 2026-10-30 · +3.5% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$4.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$279.2M cash; operating cash flow $2.7M a quarter.Report 2026-09-30
Shares outstanding50,700,429 (2026-10-30); 50,068,904 a year earlier; 48,963,717 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Nashville, Tennessee, United StatesPCAOB Form AP 2026-03-14
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$50.2M-$10.9M$5.2M$279.2M$186.1M$192.4M10-Q 2026-11-05
Q2 2026
2026-06-30
$49.0M-$8.3M$1.1M$269.3M$185.8M$186.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$47.8M-$10.5M$3.7M$272.9M$185.5M$182.9M10-Q 2026-05-05
Q4 2025
2025-12-31
$45.5M-$11.6M$919K$250.5M$185.3M$176.2M10-K 2026-03-05
Q3 2025
2025-09-30
$44.2M-$6.9M$2.2M$255.8M$184.8M$172.2M10-Q 2026-11-05
Q2 2025
2025-06-30
$45.5M$108.9M-$7.3M$243.4M$184.5M$166.3M10-Q 2026-08-06
Q1 2025
2025-03-31
$41.0M-$12.0M-$4.3M$36.1M$198.7M$160.5M10-Q 2026-05-05
Q4 2024
2024-12-31
$41.5M-$18.7M-$5.5M$34.1M$198.4M$156.8M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32023-12-21
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-05
Latest current report
FORM 8-K
8-K2026-11-05
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.1%
1 month+17.3%
3 months+31.5%
Year to date+107.2%
1 year+127.1%
From 52-week high-4.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MLTXMoonLake Immunotherapeutics$11.73-6.16%$998.3M
SVRASavara Inc.$4.46-3.77%$985.1M
SPTXSeaport Therapeutics Inc.$19.12-4.30%$1.0B
JBIOJade Biosciences Inc.$15.34-4.99%$975.3M
VSTMVerastem Inc.$7.70-5.87%$970.3M
MTRIMentari Therapeutics Inc.$19.87+6.83%$1.0B
ANROAlto Neuroscience Inc.$27.12-8.19%$1.1B
HROWHarrow Inc.$29.09-3.42%$1.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier